Experimental Study of Chemosensitivity of Human Ovarian Cancer Cisplatin-resistant Cells

【Objective】 To observe the effect of cisplatin (DDP), lobaplatin (LBP), paclitaxel (PTX) and gemcitabine (GEM) on cell proliferation of human ovarian cancer cell line SKOV3 and its cisplatin-resistant cell line SKOV3 / DDP in vitro. 【Methods】 Cultured SKOV3 and SKOV3 / DDP cells were treated by chemotherapeutics with different concentrations and at different time. Control group was treated with nothing; experimental group was incubated with drugs. Their morphological changes were observed under a phase contrast microscope. Methyl thiazolyl tetrazolium (MTT) colorimetric assay was used to detect the differences between the two cells for their sensitivity to chemotherapeutic drugs. The cell cycle and apoptosis rate were measured by flow cytometry. 【Results】 The resistance index of SKOV3 / DDP cells was (7.10 ± 2.19). Lobaplatin, paclitaxel and gemcitabine had no significant differences in influencing the cell growth inhibitory rate of both SKOV3 and SKOV3 / DDP cells. Combination of two chemotherapeutic drugs produced significant anti-proliferation effects on tumor cell growth inhibition when compared with using single drug. Lobaplatin in combination with gemcitabine or paclitaxel had more inhibitory effects on the cells. Flow cytometry analysis showed that the apoptosis percentage in SKOV3 / DDP cells was significantly lower than that in SKOV3 cells after cisplatin treatment for 48 h. There was no significant difference in cell apoptotic rate between the two cells after incubation with lobaplatin, paclitaxel and gemcitabine for 48 h. Cisplatin, lobaplatin, paclitaxel, and gemcitabine influenced the cell cycle in different phases. 【Conclusions】 Ovarian cancer SKOV3 / DDP cells show no sensitivity to cisplatin but they were non-cross-resistant to lobaplatin, paclitaxel and gemcitabine. The combined treatments of drugs in chemotherapy can synergistically inhibit the proliferation of cells. It is probably to choose gemcitabine and lobaplatin or paclitaxel plus lobaplatin for the treatment of cisplatin- resistance in ovarian cancer patients.